Efficacy and Safety of Minoxidil 5% Foam in Combination With a Botanical Hair Solution in Men With Androgenic Alopecia

April 2016 | Volume 15 | Issue 4 | Original Article | 406 | Copyright © April 2016


Terrence C. Keaney MD,a Hanh Pham MA,b Erika von Grote PhD,b and Matthew H. Meckfessel PhDc

aThe Washington Institute of Dermatologic Laser Surgery, Washington, DC
bNestle Skin Health (SHIELD), New York, NY
cGalderma Laboratories, L.P., Fort Worth, TX

Significant subject agreement with noticeably fuller-looking hair and having received compliments from others are important results, since these address the potential improvement of self-image, self-esteem, and social functioning, all variables that drive patients to seek relief and treatment for their hair loss. Ultimately, the high level of subject satisfaction with the benefits achieved by week 12, including improvement in hair volume, texture, and quality, was reflected by a significant proportion of subjects responding that they liked the study regimen, and that they would recommend it to others.
This study was limited by study design, as it was open-label, included no comparison with an active control regimen, and concluded at week 12. Additional studies designed with a longer duration, increased subject number, and active control may enhance the results obtained. Further study exploring the distinct benefit of the BHS in this regimen is necessary.

CONCLUSION

The aim of minoxidil treatment is to slow or stop the progression of hair loss and requires continuous use, therefore patient perception of treatment benefit and cosmetic acceptability are foundational in successful treatment. Important in these study results was the benefit reported by the subjects as well as the investigator as early as week 4. The favorable results demonstrated by the twice-daily use of minoxidil 5% foam in combination with the BHS suggest that this regimen is an effective treatment option for clinicians treating patients with AGA, and that it may also promote patient adherence to long-term minoxidil treatment recommendations.

DISCLOSURES

Funding/support was provided by Galderma Laboratories, L.P., Fort Worth, TX. Erika von Grote PhD, Matthew Meckfessel PhD, and Hanh Pham MA are employees of Galderma Laboratories, L.P., Fort Worth. Terrence Keaney MD has no conflicts of interest to disclose.

REFERENCES

  1. Norwood OT. Male pattern baldness: classification and incidence. South Med J. 1975;68(11):1359-1365.
  2. Messenger A. Androgenetic alopecia in men. In: Blume-Peytavi U, Tosti A, Whiting DA, Trueb RM, eds. Hair Growth and Disorders. Berlin, Heidelberg: Springer-Verlag. 2008:159-170.
  3. Blume-Peytavi U, Blumeyer A, Tosti A, et al. S1 guideline for diagnostic evaluation in androgenetic alopecia in men, women and adolescents. Br J Dermatol. 2011;164(1):5-15.
  4. Stenn KS, Paus R. Controls of hair follicle cycling. Physiol Rev. 2001;81(1):449-494.
  5. Whiting DA. Diagnostic and predictive value of horizontal sections of scalp biopsy specimens in male pattern androgenetic alopecia. J Am Acad Dermatol. 1993;28(5 pt 1):755-763.
  6. Whiting DA. Possible mechanisms of miniaturization during androgenetic alopecia or pattern hair loss. J Am Acad Dermatol. 2001;45(suppl 3):s81-s86.
  7. Deslypere JP, Young M, Wilson JD, McPhaul MJ. Testosterone and 5 alpha-dihydrotestosterone interact differently with the androgen receptor to enhance transcription of the MMTV-CAT reporter gene. Mol Cell Endocrinol. 1992;88(1-3):15-22.
  8. Wilson JD, Griffin JE, Russell DW. Steroid 5 alpha-reductase 2 deficiency. Endocr Rev. 1993;14(5):577-593.
  9. Itami S, Inui S. Role of androgen in mesenchymal epithelial interactions in human hair follicle. J Investig Dermatol Symp Proc. 2005;10(3):209-211.
  10. Yang YC, Fu HC, Wu CY, Wei KT, Huang KE, Kang HY. Androgen receptor accelerates premature senescence of human dermal papilla cells in association with DNA damage. PLoS One. 2013;8(11):e79434.
  11. Otberg N, Finner AM, Shapiro J. Androgenetic alopecia. Endocrinol Metab Clin North Am. 2007;36(2):379-398.
  12. Mahé YF, Michelet JF, Billoni N, et al. Androgenetic alopecia and microinflammation. Int J Dermatol. 2000;39(8):576-584.
  13. Severi G, Sinclair R, Hopper JL, et al. Androgenetic alopecia in men aged 40-69 years: prevalence and risk factors. Br J Dermatol. 2003;149(6):1207-1213.
  14. Krupa Shankar D, Chakravarthi M, and Shilpakar R. Male androgenetic alopecia: population-based study in 1,005 subjects. Int J Trichology. 2009;1(2):131-133.
  15. Cash TF. The psychosocial consequences of androgenetic alopecia: a review of the research literature. Br J Dermatol. 1999;141(3):398-405.
  16. Katz HI, Hien NT, Prawer SE, Goldman SJ. Long-term efficacy of topical minoxidil in male pattern baldness. J Am Acad Dermatol. 1987;16(3 pt 2):711-718.
  17. Long-term (5-year) multinational experience with finasteride 1 mg in the treatment of men with androgenetic alopecia. Finasteride Male Pattern Hair Loss Study Group. Eur J Dermatol. 2002;12(1):38-49.
  18. Messenger AG, Rundegren J. Minoxidil: mechanisms of action on hair growth. Br J Dermatol. 2004;150(2):186-194.
  19. Olsen EA, Dunlap FE, Funicella T, et al. A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men. Am Acad Dermatol. 2002;47(3):377-385.
  20. Lachgar S, Charveron M, Gall Y, Bonafe JL. Minoxidil upregulates the expression of vascular endothelial growth factor in human hair dermal papilla cells. Br J Dermatol. 1998;138(3):407-411.
  21. Saraswat A, Kumar B. Minoxidil vs finasteride in the treatment of men with androgenetic alopecia. Arch Dermatol. 2003;139(9):1219-1221.
  22. Traish AM, Hassani J, Guay AT et al. Adverse side effects of 5 α-reductase inhibitors therapy: persistent diminished libido and erectile dysfunction and depression in a subset of patients. J. Sex Med. 2011;8(3):872-884.
  23. D’Amico AV, Roehrborn CG. Effect of 1 mg / day finasteride on concentrations of serum prostate-specific antigen in men with androgenic alopecia: a randomised controlled trial. Lancet Oncol. 2007;8(1):21-25.
  24. Hu R, Xu F, Sheng Y, et al. Combined treatment with oral finasteride and topical minoxidil in male androgenetic alopecia: a randomized and comparative study in Chinese patients. Dermatol Ther. 2015;28(5):303-308.
  25. Semalty M, Semalty A, Joshi GP, Rawat MS. Hair growth and rejuvenation: an overview. J Dermatol Treat. 2011;22(3):123-132.
  26. Patel S, Sharma V, Chauhan NS, Thakur M, Dixit VK. Hair growth: focus on herbal therapeutic agent. Curr Drug Discov Technol. 2015;12(1):21-42.
  27. Uebel CO, da Silva JB, Cantarelli D, Martins P. The role of platelet plasma growth factors in male pattern baldness surgery. Plast Reconstr Surg. 2006;118(6):1458-1466.
  28. Marx RE. Platelet-rich plasma: evidence to support its use. J Oral Maxillofac Surg. 2004;62(4):489-496.
  29. Jimenez JJ, Wikramanayake TC, Bergfeld W, et al. Efficacy and safety of a low-level laser device in the treatment of male and female pattern hair loss: a multicenter, randomized, sham device-controlled, double-blind study. Am J Clin Dermatol. 2014;15(2):115-127.
  30. Bernstein RM, Rassman WR. Follicular transplantation: Patient evaluation and surgical planning. Dermatol Surg. 1997;23(9):771-784.
  31. Friedman ES, Friedman PM, Cohen DE, Washenik K. Allergic contact dermatitis to topical minoxidil solution: etiology and treatment. J Am Acad Dermatol. 2002;46(2):309-312.

AUTHOR CORRESPONDENCE

Terrence C. Keaney MD…….................................. TKeaney@skinlaser.com
Close Menu